ArticlePharmacological reports : PR2025
The xanthine oxidase inhibitor allopurinol prevents thermal and mechanical hyperalgesia in a mouse model of peripheral mononeuropathy.
Article in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modulation of Spinal Mu-Opioid Receptor Expression by Selective Adenosine A1 and A3 Receptor Agonists and Allopurinol in a Rat Model of Neuropathic Pain.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllopurinol is a potent xanthine oxidase inhibitor commonly used to treat hyperuricemia and gout. Purines have been implicated in various mechanisms of pain modulation. This study investigated whether xanthine oxidase inhibition by allopurinol could enhance endogenous purinergic activity and produce antinociceptive effects in a neuropathic pain model in mice.
methodsMale mice received intraperitoneal injections of allopurinol (50–200 mg/kg) or vehicle (10% Tween 80) and were subjected to a partial sciatic nerve ligation (PSNL) model of neuropathic pain. Behavioral assessments evaluated thermal and mechanical hyperalgesia. The involvement of adenosine receptors was explored using specific antagonists. Locomotor activity was assessed to rule out motor impairment. Cerebrospinal fluid (CSF) samples were collected to quantify purine levels.
resultsAllopurinol induced dose-dependent antinociceptive effects in the neuropathic pain model. The antinociceptive response was partially reversed by the A1 adenosine receptor antagonist DPCPX, but not by the A2A antagonist SCH58261. No significant motor deficits were observed at doses up to 200 mg/kg. Biochemical analysis revealed increased CSF concentrations of xanthine, inosine, and guanosine, and decreased uric acid levels following allopurinol administration.
conclusionsSystemic administration of allopurinol produced antinociceptive effects in a neuropathic pain model, with significant reductions in mechanical allodynia and effects on thermal hyperalgesia mediated partly by A1 adenosine receptors, as evidenced by main treatment effects and specific time-point differences where interactions were significant. These effects were accompanied by altered CSF purine levels without motor impairment. The findings support further investigation of xanthine oxidase inhibitors, such as allopurinol, as potential therapeutic agents for chronic neuropathic pain.
Indexed as
Identifiers
40887558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.